EUnetHTA final report for 24-hour blood pressure measurement device Mobil-O- Graph® published

07

Aug 2020

On July 03, 2020, the network of European HTA agencies, EUnetHTA, published the final report for the Rapid Relative Effectiveness Assessment OTCA24 ‘The 24-hour blood pressure measurement device Mobil-O- Graph® with the built-in algorithm ARCSolver® to measure arterial stiffness for the optimization of hypertension treatment.”

Mobil-O-Graph®(I.E.M, Stolberg, Germany) is a peripheral blood pressure measuring. It can be coupled with ARCSolver® (Austrian Institute of Technology) algorithm that uses pulse wave analysis to calculate aortic systolic blood pressure (aSBP) and Augmentation Index (AIx) in combination with the oscillometric blood pressure measurement, and therefore arterial stiffness. Arterial stiffness parameters that can also be obtained using other devices help to assess hypertension more precisely and to define the cardiovascular risk.

The study objective was to find out whether the pulse wave analysis device Mobil-O-Graph® with the ARCSolver® algorithm in the out-patient setting is more effective and/or safer in patients at risk of cardiovascular events or in hypertension diagnosing and monitoring, compared to current standard practice.

A systematic literature search was conducted using the Embase.com platform, including Medline and Embase databases. Additionally, the Center for Research and Dissemination databases and clinicaltrials.gov were searched.

A total of 14 studies were found that describe the efficacy of Mobil-O-Graph® with ARCSolver® for primary and secondary prevention of cardiovascular risk as well as for diagnosis and monitoring of hypertension. No evidence was found on safety. No ongoing, non-published, relevant clinical trials were found.

ARCSolver®, as part of Mobil-O-Graph® is currently being reimbursed in Austria. No feedback regarding reimbursement was received from EUnetHTA partners.

It is not clear whether Mobil-O-Graph® with ARCSolver® is equal, less, or more effective than comparators in relation to patient outcome and therapeutic or diagnostic efficacy. The current literature on Mobil-O-Graph® with ARCSolver® focuses on technical efficacy and characteristics compared to other devices that measure arterial stiffness. There is moderate-quality evidence that Mobil-O-Graph® technical efficiency is equivalent to other devices, using an algorithm or carotid-femoral pulse wave velocity. There is a lack of evidence whether or not Mobil-O-Graph® with ARCSolver® is more effective and safer and lead patients to better health care services and treatment to hypertension control or cardiovascular events. Further studies need to concentrate on diagnostic accuracy compared to other cardiovascular risk assessment tools and to common blood pressure measurement in hypertension.

The full details in English can be found here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more